{"id":"brivaracetam-film-coated-tablet","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Somnolence"},{"rate":"8-12","effect":"Fatigue"},{"rate":"7-10","effect":"Dizziness"},{"rate":"5-8","effect":"Headache"},{"rate":"5-7","effect":"Irritability"},{"rate":"4-6","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL607400","moleculeType":"Small molecule","molecularWeight":"212.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brivaracetam is a high-affinity ligand for SV2A, a protein involved in synaptic vesicle trafficking and neurotransmitter release. By binding to SV2A, it modulates neuronal activity and reduces the propensity for seizure generation. This mechanism is similar to levetiracetam but with higher selectivity and potency for SV2A.","oneSentence":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:07.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in patients with epilepsy"},{"name":"Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy"}]},"trialDetails":[{"nctId":"NCT06315322","phase":"PHASE3","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-07-10","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":120},{"nctId":"NCT05109234","phase":"PHASE3","title":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-03-30","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":84},{"nctId":"NCT03083665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-22","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":449},{"nctId":"NCT03250377","phase":"PHASE3","title":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-05","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":207},{"nctId":"NCT04882540","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-05-19","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT00464269","phase":"PHASE3","title":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":400},{"nctId":"NCT02088957","phase":"PHASE2","title":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-03","conditions":"Nonconvulsive Electrographic Seizures","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brivaracetam Film-coated tablet","genericName":"Brivaracetam Film-coated tablet","companyName":"UCB Biopharma SRL","companyId":"ucb-biopharma-srl","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) in the brain to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in patients with epilepsy, Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}